News

Video

LB-102 for the Treatment of Acutely Exacerbated Schizophrenia: Insights From the Principal Investigator

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society. LB-102 is a once-daily orally administered novel dopamine D2/3/5-HT7 inhibitor and potential first-in-class benzamide antipsychotic, in adult patients with acute schizophrenia.

Kane served as the principal investigator of NOVA, a phase 2 randomized, double-blind, placebo-controlled, multi-center inpatient trial evaluating the efficacy and safety of a once-daily oral dose of LB-102 in 359 adults, aged 18 to 55 with DSM-5 diagnosis of acutely exacerbated schizophrenia. Initial data from NOVA were shared in early January; this presentation shares additional data from this trial.

The primary endpoint of NOVA—a clinically meaningful change in Positive and Negative Syndrome Scale (PANSS) total score at week 4—was achieved with a high degree of statistical significance at all doses. The study also measured mean change from baseline in Clinical Global Impression of Severity (CGI-S) score, which rates illness severity on a scale from 1 (normal) to 7 (extremely ill) and has been shown to correlate with PANSS, as a secondary endpoint. At week 4 of the study, participants treated with the 50 mg dose (n=107) achieved a mean change in baseline CGI-S score of -0.72 compared with placebo (P=0.0008). Those who received the 75 mg dose (n=108) achieved a mean change in baseline CGI-S score of -0.67 compared with placebo (P=0.0048). Treatment with the exploratory dose of 100 mg (n=36) resulted in a mean change in baseline CGI-S score of -0.84 compared with placebo (P=0.0026).

"The results are very encouraging," Kane told Psychiatric Times. "Those patient randomly assigned to LB-102 experienced significant improvement on the PANSS total score between baseline and week 4."

You can read more about this data here.

Dr Kane is a professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the codirector of the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.

Related Videos
sc
schizophrenia
clozapine
brain
cognition
clock
clozapine
steering wheel
schizophrenia
Christoph U. Correll
© 2025 MJH Life Sciences

All rights reserved.